PMID- 33686713
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 7
DP  - 2021 Apr
TI  - Long noncoding RNA MCM3AP-AS1 enhances cell proliferation and metastasis in 
      colorectal cancer by regulating miR-193a-5p/SENP1.
PG  - 2470-2481
LID - 10.1002/cam4.3830 [doi]
AB  - BACKGROUND: Accumulating evidences have shown that long noncoding RNAs (lncRNAs) 
      play key roles in many diseases, including cancer. Several studies reported that 
      MCM3AP antisense RNA 1 (MCM3AP-AS1) was associated with the tumorigenesis and 
      progression. However, the specific function and mechanism of MCM3AP-AS1 in 
      colorectal cancer (CRC) have not been fully understood. METHODS: The expression 
      of MCM3AP-AS1 was detected by quantitative reverse transcription PCR (RT-qPCR) in 
      CRC tissues and matched noncancerous tissues (NCTs). CCK-8 assay, colony 
      formation assay, transwell assay, xenograft and lung metastasis mouse models were 
      used to examine the tumor-promoting function of MCM3AP-AS1 in vitro and in vivo. 
      The binding relationship between MCM3AP-AS1, miR-193a-5p and sentrin-specific 
      peptidase 1 (SENP1) were screened and identified by databases, RT-qPCR, dual 
      luciferase reporter assay and western blot. RESULTS: In the present study, we got 
      that the expression of MCM3AP-AS1 was higher in CRC tissues than in paired NCTs, 
      and increased MCM3AP-AS1 expression was associated with adverse outcomes in CRC 
      patients. Functional experiments in vitro revealed that silencing of MCM3AP-AS1 
      could inhibit the proliferation, colony formation, migratory, and invasive 
      abilities of CRC cells. The mouse models of xenograft and lung metastasis further 
      confirmed that in vivo silencing MCM3AP-AS1 could significantly inhibit the 
      growth and metastasis of CRC. Further mechanism studies indicated that MCM3AP-AS1 
      could sponge miR-193a-5p and inhibit the activity of it. What is more, SENP1 was 
      proved to be a novel target of miR-193a-5p and could be upregulated by 
      MCM3AP-AS1. At last, we observed that SENP1 overexpression in CRC tissues was 
      closely related to unfavorable prognosis. CONCLUSION: Taken together, we 
      identified in CRC the MCM3AP-AS1/miR-193a-5p/SENP1 regulatory axis, which affords 
      a therapeutic possibility for CRC.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhou, Mingyue
AU  - Zhou M
AD  - Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan 
      University, Wuxi, Jiangsu, China.
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Bian, Zehua
AU  - Bian Z
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Liu, Bingxin
AU  - Liu B
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Colorectal Surgery, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, Jiangsu, China.
FAU - Cao, Yulin
AU  - Cao Y
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Cui, Kaisa
AU  - Cui K
AUID- ORCID: 0000-0001-7255-2689
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Sun, Shengbai
AU  - Sun S
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Li, Jiuming
AU  - Li J
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Zhang, Jia
AU  - Zhang J
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Li, Chaoqun
AU  - Li C
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Yao, Surui
AU  - Yao S
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Yin, Yuan
AU  - Yin Y
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Fei, Bojian
AU  - Fei B
AD  - Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan 
      University, Wuxi, Jiangsu, China.
FAU - Huang, Zhaohui
AU  - Huang Z
AUID- ORCID: 0000-0002-0117-9976
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210308
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (MIRN193 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Antisense)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 2.3.1.- (Acetyltransferases)
RN  - EC 2.3.1.- (MCM3AP protein, human)
RN  - EC 3.4.- (SENP1 protein, human)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
SB  - IM
MH  - Acetyltransferases/genetics/*metabolism
MH  - Animals
MH  - Cell Proliferation/genetics
MH  - Colorectal Neoplasms/genetics/*metabolism/mortality/pathology
MH  - Cysteine Endopeptidases/*metabolism
MH  - Gene Silencing
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - Lung Neoplasms/secondary
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - MicroRNAs/*metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis/genetics
MH  - Neoplasm Transplantation
MH  - Prognosis
MH  - RNA, Antisense/metabolism
MH  - RNA, Long Noncoding/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Stem Cell Assay
MH  - Up-Regulation
PMC - PMC7982620
OTO - NOTNLM
OT  - MCM3AP antisense RNA 1
OT  - SENP1
OT  - colorectal cancer
OT  - long noncoding RNAs
OT  - microRNAs
COIS- The authors declare that they have no conflict of interest.
EDAT- 2021/03/10 06:00
MHDA- 2021/07/20 06:00
PMCR- 2021/03/08
CRDT- 2021/03/09 06:17
PHST- 2021/02/01 00:00 [revised]
PHST- 2020/11/08 00:00 [received]
PHST- 2021/02/05 00:00 [accepted]
PHST- 2021/03/10 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2021/03/09 06:17 [entrez]
PHST- 2021/03/08 00:00 [pmc-release]
AID - CAM43830 [pii]
AID - 10.1002/cam4.3830 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Apr;10(7):2470-2481. doi: 10.1002/cam4.3830. Epub 2021 Mar 8.